The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Pralatrexate
Pralatrexate · PRALATREXATE 20 mg/mL · Injection · Intravenous · Dr.Reddy's Laboratories Inc.,
NDC 43598-0342-11 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Medicare Part B (ASP)
Payment limit per 1 MG
$386.122
HCPCS J9307 · Jul 1, 2026 quarter · typically ASP + 6%
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA206183
- TE code
- AP
- Approval date
- Mar 10, 2025
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Pralatrexate (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Acrotech Biopharma Inc | PRALATREXATE 20 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Acrotech Biopharma Inc | PRALATREXATE 40 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Dr.Reddy's Laboratories Inc., | PRALATREXATE 20 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Dr.Reddy's Laboratories Inc., | PRALATREXATE 40 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | PRALATREXATE 20 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | PRALATREXATE 40 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Pralatrexate — NDC 43598-0342-11," retrieved September 3, 2026, https://drugdashboards.com/drug/43598034211.
Free to cite with attribution — see how the data is put together.